Literature DB >> 25535908

miR-155 Regulates Glioma Cells Invasion and Chemosensitivity by p38 Isforms In Vitro.

Qiang Liu1,2, Ran Zou1, Rouxi Zhou3, Chaofan Gong3, Zhifei Wang2, Tao Cai2, Chaochao Tan2, Jiasheng Fang1.   

Abstract

The critical role of microRNAs in cancer development has been extensively described. miRNAs are both specific markers and putative therapy targets. miR-155 has been identified to be an oncomiRNA and is highly expressed in several solid cancers, including glioblastoma. In this study, we found that miR-155 is a good potential therapy target. Knockdown of miR-155 sensitizes glioma cells to the chemotherapy of temozolomide (TMZ) by targeting the p38 isoforms mitogen-activated protein kinase 13 [MAPK13, also known as p38 MAPKδ or stress-activated protein kinase 4 (SAPK4)] and MAPK14 (also known as p38 MAPKα). As tumor suppressor genes, MAPK13 and MAPK14 play important roles in lowering the accumulation of reactive oxygen species (ROS), inducing cell apoptosis, and slowing the progression of cancer. Knockdown of miR-155 enhanced the anticancer effect of TMZ on glioma by targeting the MAPK13 and MAPK14-mediated oxidative stress and apoptosis, but did not affect the secretion of MMP2 and MMP9.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  CHEMOSENSITIVITY; GLIOBLASTOMA; MAPK; REACTIVE OXYGEN SPECIES; TEMOZOLOMIDE; microRNA

Mesh:

Substances:

Year:  2015        PMID: 25535908     DOI: 10.1002/jcb.25073

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  28 in total

1.  miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer.

Authors:  Leonie Mühlberg; Benjamin Kühnemuth; Eithne Costello; Victoria Shaw; Bence Sipos; Magdalena Huber; Heidi Griesmann; Sebastian Krug; Marvin Schober; Thomas M Gress; Patrick Michl
Journal:  Oncoimmunology       Date:  2016-05-09       Impact factor: 8.110

2.  miR-139 Functions as An Antioncomir to Repress Glioma Progression Through Targeting IGF-1 R, AMY-1, and PGC-1β.

Authors:  Hong Wang; Xi Yan; Li-Ya Ji; Xi-Tuan Ji; Ping Wang; Shi-Wen Guo; San-Zhong Li
Journal:  Technol Cancer Res Treat       Date:  2016-02-10

3.  i-Modern: Integrated multi-omics network model identifies potential therapeutic targets in glioma by deep learning with interpretability.

Authors:  Xingxin Pan; Brandon Burgman; Erxi Wu; Jason H Huang; Nidhi Sahni; S Stephen Yi
Journal:  Comput Struct Biotechnol J       Date:  2022-06-30       Impact factor: 6.155

4.  High expression of miR-9 in CD133+ glioblastoma cells in chemoresistance to temozolomide.

Authors:  Jessian L Munoz; Vivian Rodriguez-Cruz; Pranela Rameshwar
Journal:  J Cancer Stem Cell Res       Date:  2015-02-27

Review 5.  A Special View of What Was Almost Forgotten: p38δ MAPK.

Authors:  Débora Bublitz Anton; Rodrigo Gay Ducati; Luís Fernando Saraiva Macedo Timmers; Stefan Laufer; Márcia Inês Goettert
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

Review 6.  Roles of the miR-155 in Neuroinflammation and Neurological Disorders: A Potent Biological and Therapeutic Target.

Authors:  Seyed Hamidreza Rastegar-Moghaddam; Alireza Ebrahimzadeh-Bideskan; Sara Shahba; Amir Mohammad Malvandi; Abbas Mohammadipour
Journal:  Cell Mol Neurobiol       Date:  2022-02-02       Impact factor: 5.046

7.  miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase.

Authors:  Huiyuan Chen; Xinyi Li; Wenbin Li; Huyong Zheng
Journal:  J Transl Med       Date:  2015-02-21       Impact factor: 5.531

Review 8.  Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).

Authors:  Giulio Cabrini; Enrica Fabbri; Cristiana Lo Nigro; Maria Cristina Dechecchi; Roberto Gambari
Journal:  Int J Oncol       Date:  2015-05-29       Impact factor: 5.650

Review 9.  MiRNA-based therapeutic intervention of cancer.

Authors:  Srivatsava Naidu; Peter Magee; Michela Garofalo
Journal:  J Hematol Oncol       Date:  2015-06-11       Impact factor: 17.388

10.  LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.

Authors:  Xin He; Jie Sheng; Wei Yu; Kejian Wang; Shujuan Zhu; Qian Liu
Journal:  Cell Mol Neurobiol       Date:  2020-06-11       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.